Figure 1. The age structure of patients treated with remdesivir during Delta (n=490) and Omicron (n=272) surges.
Comorbidities were significantly more frequently reported during the Omicron prevalence period (75.5 vs. 93%, p<0.001), and these patients significantly more often presented with vascular diseases such as stroke (3.1 vs. 12.5%, p<0.001), ischemic heart disease (9.4 vs. 23.5%, p<0.001) (Table 1).
A comparison of the baseline clinical status of RDV-treated patients showed a significantly lower percentage of asymptomatic or in stable condition with saturation >95% (12% vs. 27.9%, p<0.001) hospitalized during the Delta-dominant period, while the percentage of patients in unstable condition with saturation ≤95% or ARDS was significantly higher compared to the Omicron wave (87.9 vs. 72.1%, p<0.001) (Table 2).
Table 2. Baseline clinical status and laboratory parameters (mean ± SD) of patients hospitalized during Delta and Omicron waves with regard to RDV treatment.